2026 Trends: A Year Of Change & Opportunity

26 isn’t just another year in market access — it’s a turning point. In this episode of Let’s Talk Rare , P4A dives into the trends that are about to reshape how rare disease therapies reach patients across Europe — and trust us, the ground is moving. Policy is back in the spotlight. With the EU Pharmaceutical Strategy resurfacing, the big question is: How do we reward innovation and keep medicines affordable? The balance is shifting, and everyone — manufacturers, regulators, patients — will feel it. Meanwhile, AI is no longer hype . It’s influencing research, pricing models, even HTA decisions. Faster insights, smarter systems… but also tough questions about transparency, trust, and who — or what — is really making the call. And patients? They’re not sitting on the sidelines anymore. Patient engagement is becoming central to access decisions, pushing HTA bodies toward more inclusive frameworks, real-world perspectives, and maybe even a rethink of traditional ICER thresholds. Bottom line: 2026 is a year of change — and serious opportunity. The winners will be the ones who adapt early. 🎧 Tune in to P4A’s Let’s Talk Rare to get ahead of the trends shaping the future of market access in Europe.

You can listen to 2026 Trends: A Year Of Change & Opportunity online on Radio and Podcast. Open the player on this page to stream the available audio.

2026 Trends: A Year Of Change & Opportunity is an episode from Rare Disease, Cell & Gene Therapy Monthly RoundUp by Partners4Access.

This episode is 00:17:08 long.

This episode was published on Jan 30, 2026.

Yes. Use the heart button on the episode page to add it to your favorite episodes list.

Yes. This page shows related episodes from Rare Disease, Cell & Gene Therapy Monthly RoundUp when more episodes are available from the podcast feed.